Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an announcement.
Race Oncology Ltd has announced an investor briefing in Hong Kong on October 14, 2025, where key executives will present an overview of the company and discuss clinical development plans, including the recent opening of clinical trial sites in Hong Kong. This event marks a significant step in the company’s global expansion efforts, potentially impacting its industry positioning and offering new opportunities for stakeholder engagement.
More about Race Oncology Ltd.
Race Oncology Ltd is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Their lead asset, RCDS1 (E,E-bisantrene), is an anticancer agent with a well-characterized safety profile. The company is advancing a proprietary formulation, RC220, to address unmet needs in oncology, focusing on combinations with anthracycline for enhanced anticancer activity and cardioprotection in solid tumors. Race Oncology collaborates with various institutions and is exploring partnerships to accelerate global access to RC220.
Average Trading Volume: 132,926
Technical Sentiment Signal: Buy
Current Market Cap: A$312.8M
See more data about RAC stock on TipRanks’ Stock Analysis page.